Syngene International Limited Announces Audited Consolidated Financial Results for the Fourth Quarter and Year Ended March 31, 2017
April 27, 2017 at 10:12 am EDT
Share
Syngene International Limited announced audited consolidated financial results for the fourth quarter and year ended March 31, 2017. For the quarter, the company reported revenue from operations of INR 2,913 million against INR 3,315 million for the same period a year ago. Total income was INR 3,152 million against INR 3,344 million for the same period a year ago. Profit before exceptional items and tax was INR 904 million compared with INR 933 million a year ago. Profit before taxation was INR 904 million against INR 933 million for the same period a year ago. Net Profit for the period was INR 784 million against INR 790 million for the same period a year ago. Diluted earnings per share were INR 3.95 per share against INR 4.00 for the same period a year ago. EBITDA was INR 1,240 million against INR 1,200 million for the same period a year ago.
For the year, the company reported revenue from operations of INR 12,009 million against INR 11,070 million for the same period a year ago. Total income was INR 12,716 million against INR 11,133 million for the same period a year ago. Profit before exceptional items and tax was INR 3,465 million compared with INR 2,810 million a year ago. Profit before taxation was INR 3,465 million against INR 2,810 million for the same period a year ago. Net Profit for the period was INR 2,873 million against INR 2,408 million for the same period a year ago. Diluted earnings per share were INR 14.55 per share against INR 12.19 for the same period a year ago. EBITDA was INR 4,780 million against INR 3,870 million for the same period a year ago.
Syngene International Limited is an integrated research, development, and manufacturing services company. The Company is engaged in providing contract research and manufacturing services from lead generation to clinical supplies to pharmaceutical and biotechnology companies worldwide. Its services include drug discovery and development capabilities in medicinal chemistry, biology, in vivo pharmacology, toxicology, custom synthesis, process research and development, current good manufacturing practice (cGMP) manufacturing, formulation, and analytical development, along with clinical development services. It offers SynVent, a therapeutic discovery and development platform for executing drug discovery projects. SynVent's portfolio covers modalities and therapeutic areas ranging from small molecule inhibitors to targeted protein stabilization. It serves the pharmaceutical, biotechnology, and specialty chemical sectors, among others. It operates multi-modal biologics manufacturing facility.